Autres langues TScan Therapeutics, Inc.

Actions

TCRX

US89854M1018

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,3145 ^USD	-0,94%		-13,60%	-68,55%

02/09	TScan Therapeutics, Inc. : Needham & Co. moins optimiste	ZM
02/09	TScan Therapeutics, Inc. : Wedbush n'est plus acheteur	ZM

Autres langues

21/09	TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from S&P Global BMI Index
02/09	TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
02/09	TScan Therapeutics Advances In Vivo-Engineered TCR-T Candidates for Solid Tumors and Provides Updates on Heme Malignancies and Autoimmunity Programs
18/08	TScan Therapeutics, Inc. And Amgen Inc. Terminate Research Collaboration And License Agreement
12/08	TScan Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
30/07	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
29/07	Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies
29/07	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
29/07	TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
24/06	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
24/06	TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
22/06	TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
22/06	TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment
22/06	TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
03/06	Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101
03/06	Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
06/05	TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
27/04	TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
08/04	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
08/04	TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
02/04	TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026
19/03	Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
19/03	Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care